-
Je něco špatně v tomto záznamu ?
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries
X. Li, J. Bilcke, AW. van der Velden, R. Bruyndonckx, S. Coenen, E. Bongard, M. de Paor, S. Chlabicz, M. Godycki-Cwirko, N. Francis, R. Aabenhus, HC. Bucher, A. Colliers, A. De Sutter, A. Garcia-Sangenis, D. Glinz, NJ. Harbin, K. Kosiek, M....
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
grant HEALTH-F3-2013-602525
European Commission
NLK
ProQuest Central
od 2001 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2001 do Před 1 rokem
Health Management Database (ProQuest)
od 2001 do Před 1 rokem
Public Health Database (ProQuest)
od 2001 do Před 1 rokem
- MeSH
- analýza nákladů a výnosů MeSH
- chřipka lidská * farmakoterapie MeSH
- dítě MeSH
- dospělí MeSH
- kvalita života MeSH
- kvalitativně upravené roky života MeSH
- lidé MeSH
- mladiství MeSH
- oseltamivir terapeutické užití MeSH
- primární zdravotní péče MeSH
- virové nemoci * MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers' expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1-€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.
Centre for Family and Community Medicine Medical University of Lodz Lodz Poland
Département de Santé Publique Hôpital de l'Archet Nice France
Department of Family Medicine and Population Health University of Antwerp Antwerp Belgium
Department of Family Medicine Medical University of Bialystok Białystok Poland
Department of Public Health and Primary Care Gent University Gent Belgium
DRC Drug Research Center LLC Balatonfüred Hungary
Family Doctors' Clinic Lodz Poland
FDC Mano šeimos gydytojas Klaipeda Lithuania
General Practice and Primary Health Care at the School of Medicine University of Crete Crete Greece
Julius Center for Health Sciences and Primary Care University Medical Center Utrecht The Netherlands
Malia Surgery Kastelli HC Heraklio Greece
RCSI Department of General Practice 123 St Stephens Green Dublin 2 Ireland
The Nuffield Department of Primary Care Health Sciences University of Oxford Oxford UK
University Institute in Primary Care Research Jordi Gol Via Roma Health Centre Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010844
- 003
- CZ-PrNML
- 005
- 20230801132642.0
- 007
- ta
- 008
- 230718s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10198-022-01521-2 $2 doi
- 035 __
- $a (PubMed)36131214
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Li, Xiao $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium. xiao.li@uantwerpen.be $1 https://orcid.org/0000000219181791
- 245 10
- $a Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries / $c X. Li, J. Bilcke, AW. van der Velden, R. Bruyndonckx, S. Coenen, E. Bongard, M. de Paor, S. Chlabicz, M. Godycki-Cwirko, N. Francis, R. Aabenhus, HC. Bucher, A. Colliers, A. De Sutter, A. Garcia-Sangenis, D. Glinz, NJ. Harbin, K. Kosiek, M. Lindbæk, C. Lionis, C. Llor, R. Mikó-Pauer, R. Radzeviciene Jurgute, B. Seifert, PD. Sundvall, P. Touboul Lundgren, N. Tsakountakis, TJ. Verheij, H. Goossens, CC. Butler, P. Beutels, ALIC4Etrial investigators
- 520 9_
- $a BACKGROUND: Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries. METHODS: Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers' and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed. RESULTS: The healthcare payers' expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1-€35 per patient). CONCLUSION: Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers' perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a analýza nákladů a výnosů $7 D003362
- 650 _2
- $a oseltamivir $x terapeutické užití $7 D053139
- 650 12
- $a chřipka lidská $x farmakoterapie $7 D007251
- 650 _2
- $a kvalita života $7 D011788
- 650 12
- $a virové nemoci $7 D014777
- 650 _2
- $a kvalitativně upravené roky života $7 D019057
- 650 _2
- $a primární zdravotní péče $7 D011320
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bilcke, Joke $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium $1 https://orcid.org/0000000157205291
- 700 1_
- $a van der Velden, Alike W $u Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands $1 https://orcid.org/0000000294432837
- 700 1_
- $a Bruyndonckx, Robin $u Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Data Science Institute (DSI), Hasselt University, Hasselt, Belgium $u Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium $1 https://orcid.org/0000000242172869
- 700 1_
- $a Coenen, Samuel $u Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium $1 https://orcid.org/0000000212388052
- 700 1_
- $a Bongard, Emily $u The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK $1 https://orcid.org/0000000159576280
- 700 1_
- $a de Paor, Muirrean $u RCSI Department of General Practice, 123 St Stephens Green, Dublin 2, Ireland
- 700 1_
- $a Chlabicz, Slawomir $u Department of Family Medicine, Medical University of Bialystok, Białystok, Poland $1 https://orcid.org/0000000150224588
- 700 1_
- $a Godycki-Cwirko, Maciek $u Centre for Family and Community Medicine, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Francis, Nick $u School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK $1 https://orcid.org/0000000189397312
- 700 1_
- $a Aabenhus, Rune $u Section and Research Unit of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000193542236
- 700 1_
- $a Bucher, Heiner C $u Division of Infectious Diseases and Hospital Hygiene, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
- 700 1_
- $a Colliers, Annelies $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
- 700 1_
- $a De Sutter, An $u Department of Public Health and Primary Care (Centre for Family Medicine), Gent University, Gent, Belgium $1 https://orcid.org/0000000225408307
- 700 1_
- $a Garcia-Sangenis, Ana $u University Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain $1 https://orcid.org/0000000266896466
- 700 1_
- $a Glinz, Dominik $u Department of Clinical Research, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland $1 https://orcid.org/0000000335098186
- 700 1_
- $a Harbin, Nicolay J $u Department of General Practice, Antibiotic Center for Primary Care, Institute of Health and Society, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000230056908
- 700 1_
- $a Kosiek, Katarzyna $u Family Doctors' Clinic, Lodz, Poland
- 700 1_
- $a Lindbæk, Morten $u Research Leader Antibiotic Centre for Primary Care, Department of General Practice, University of Oslo, Oslo, Norway
- 700 1_
- $a Lionis, Christos $u General Practice and Primary Health Care at the School of Medicine, University of Crete, Crete, Greece $1 https://orcid.org/0000000293242839
- 700 1_
- $a Llor, Carl $u University Institute in Primary Care Research Jordi Gol, Via Roma Health Centre, Barcelona, Spain $u Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000016644717X
- 700 1_
- $a Mikó-Pauer, Réka $u DRC Drug Research Center LLC, Balatonfüred, Hungary
- 700 1_
- $a Radzeviciene Jurgute, Ruta $u FDC Mano šeimos gydytojas, Klaipeda, Lithuania
- 700 1_
- $a Seifert, Bohumil $u Institute of General Practice, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0000000268818840 $7 xx0017737
- 700 1_
- $a Sundvall, Pär-Daniel $u General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden $u Research, Education, Development and Innovation, Primary Health Care, Region Västra Götaland, Sandared, Sweden $1 https://orcid.org/000000019889509X
- 700 1_
- $a Touboul Lundgren, Pia $u Département de Santé Publique, Hôpital de l'Archet, Nice, France
- 700 1_
- $a Tsakountakis, Nikolaos $u Malia Surgery, Kastelli HC, Heraklio, Greece
- 700 1_
- $a Verheij, Theo J $u Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
- 700 1_
- $a Goossens, Herman $u Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
- 700 1_
- $a Butler, Christopher C $u The Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 700 1_
- $a Beutels, Philippe $u Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Campus Drie Eiken, room D.S.221, Universiteitsplein 1, 2610, Antwerp, Belgium $1 https://orcid.org/0000000150343595
- 710 2_
- $a ALIC4Etrial investigators
- 773 0_
- $w MED00007432 $t The European journal of health economics : HEPAC : health economics in prevention and care $x 1618-7601 $g Roč. 24, č. 6 (2023), s. 909-922
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36131214 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132638 $b ABA008
- 999 __
- $a ok $b bmc $g 1963328 $s 1197109
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 24 $c 6 $d 909-922 $e 20220922 $i 1618-7601 $m The European journal of health economics $n Eur J Health Econ $x MED00007432
- GRA __
- $a grant HEALTH-F3-2013-602525 $p European Commission
- LZP __
- $a Pubmed-20230718
